The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors-Reference-Cited by-同舟云学术

The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors

Published:2015-12-14 Issue:4 Volume:31 Page:815-827
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Toscani Denise¹,Palumbo Carla²,Dalla Palma Benedetta¹³,Ferretti Marzia²,Bolzoni Marina¹,Marchica Valentina¹,Sena Paola²,Martella Eugenia⁴,Mancini Cristina⁴,Ferri Valentina¹⁵,Costa Federica¹,Accardi Fabrizio¹³,Craviotto Luisa¹,Aversa Franco¹³,Giuliani Nicola¹³

Affiliation:

1. Myeloma Unit, Department of Clinical and Experimental Medicine; University of Parma; Parma Italy

2. Department of Biomedical, Metabolic, and Neural Sciences, Section of Human Morphology; University of Modena and Reggio Emilia; Modena Italy

3. Hematology Unit; “Azienda Ospedaliero-Universitaria di Parma”; Parma Italy

4. Pathology; “Azienda Ospedaliero-Universitaria di Parma”; Parma Italy

5. Department of Biotechnology and Life Sciences; University of Insubria; Varese Italy

Funder

Associazione Italiana per la Ricerca sul Cancro (AIRC)

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism